カンジダ症治療薬の世界市場レポート 2025年

カンジダ症治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR3.8％で38億3,000万米ドルに成長します。予測期間の成長は、精密医療へのアプローチ、世界の抗真菌スチュワードシッププログラム、カンジダ・オーリスの有病率の増加、抗真菌剤耐性に対する世界の取り組みに起因すると考えられます。予測期間の主な動向には、ドラッグデリバリー技術の進歩、遠隔医療と遠隔患者モニタリング、患者中心の治療、併用療法、共同研究イニシアチブなどが含まれます。

真菌感染症の有病率の増加がカンジダ症治療薬市場の成長を牽引すると予想されます。皮膚、粘膜、内臓を侵す真菌感染症は、免疫力が低下した人に多く見られます。このような感染症、特にカンジダ症の罹患率の増加は、根本的な病原体を標的とする特殊で効果的な抗真菌薬を開発・提供する機会をメーカーにもたらします。これらの薬剤は、症状の緩和、合併症の予防、回復の促進、ヘルスケア環境におけるカンジダ感染症の蔓延の抑制、患者の転帰の改善を目的としています。例えば、2024年1月、米国を拠点とする研究機関であるミネソタ大学は、真菌感染症が年間375万人以上の死亡の原因となっており、そのうち約255万人が真菌性疾患に直接関連していると報告しています。その結果、真菌感染症の増加がカンジダ症治療薬市場を促進すると予想されます。

臨床試験の増加は、カンジダ症治療薬市場の成長軌道をさらに加速させると予想されます。臨床試験は、ヒトを対象とした新しい治療、介入、薬剤、デバイスの安全性と有効性を評価することを目的とした極めて重要な調査です。カンジダ症治療薬の領域では、これらの臨床試験は、潜在的な治療の安全性と有効性をテストするための体系的で厳格な評価プラットフォームを提供することにより、重要な役割を果たしています。2023年5月にClinicalTrials.govが報告したように、登録された臨床試験の数は、米国50州および221カ国にまたがる2022年の399,499件に比べ、2023年には約437,533件に急増しました。この増加は、カンジダ症治療薬の状況を形成する臨床試験の勢いと重要性が高まっていることを裏付けています。その結果、臨床試験の急増がカンジダ症治療薬市場の成長を促進する重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界カンジダ症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のカンジダ症治療薬市場：成長率分析
• 世界のカンジダ症治療薬市場の実績：規模と成長, 2019-2024
• 世界のカンジダ症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界カンジダ症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のカンジダ症治療薬市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• 手術
• その他の治療法
• 世界のカンジダ症治療薬市場解剖学の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 口腔カンジダ症
• 外陰膣カンジダ症
• 皮膚カンジダ症
• 侵襲性カンジダ症
• 全身性カンジダ症
• 世界のカンジダ症治療薬市場投与方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射可能
• オーラル
• その他の管理方法
• 世界のカンジダ症治療薬市場患者集団別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大人
• 小児科
• 世界のカンジダ症治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界のカンジダ症治療薬市場、医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗真菌薬
• 局所治療
• 全身治療
• 世界のカンジダ症治療薬市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外科的デブリードマン
• 臓器摘出
• 世界のカンジダ症治療薬市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロバイオティクス
• 家庭療法
• ライフスタイルの変更

第7章 地域別・国別分析

• 世界のカンジダ症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のカンジダ症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• カンジダ症治療薬市場：競合情勢
• カンジダ症治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Biocon Limited Overview, Products and Services, Strategy and Financial Analysis
  • Torrent Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• AstraZeneca plc.
• GSK plc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Cipla Inc.
• Bruker Corporation
• Lupin Limited
• Galapagos NV
• Basilea Pharmaceutica Ltd.
• WOCKHARDT Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• カンジダ症治療薬市場2029：新たな機会を提供する国
• カンジダ症治療薬市場2029：新たな機会を提供するセグメント
• カンジダ症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Candidiasis, a fungal infection caused by the overgrowth of Candida species, commonly affects areas such as the mouth, throat, gut, and genital regions. The primary methods of treating candidiasis involve antifungal medications, which can be either topical (applied to the affected area) or oral (ingested), depending on the severity and location of the infection.

Candidiasis therapeutics encompass various treatment approaches, including medication, surgery, and other interventions. Medication involves the use of pharmaceutical drugs to manage or alleviate the condition. The treatments target specific anatomical sites such as oral candidiasis, vulvovaginal candidiasis, cutaneous candidiasis, invasive candidiasis, and systemic candidiasis. These medications can be administered through various routes, including injectable, oral, and others, catering to both adult and pediatric patients. The end-users for these treatments include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The candidiasis therapeutics market research report is one of a series of new reports from The Business Research Company that provides candidiasis therapeutics market statistics, including candidiasis therapeutics industry global market size, regional shares, competitors with a candidiasis therapeutics market share, detailed candidiasis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the candidiasis therapeutics industry. This candidiasis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The candidiasis therapeutics market size has grown steadily in recent years. It will grow from $3.19 billion in 2024 to $3.3 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to increased incidence of candidiasis, antibiotic use and resistance, hospital-acquired infections, shift in fungal resistance patterns, awareness and education programs.

The candidiasis therapeutics market size is expected to see steady growth in the next few years. It will grow to $3.83 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to precision medicine approaches, global antifungal stewardship programs, increasing prevalence of candida auris, global efforts against antifungal resistance. Major trends in the forecast period include advancements in drug delivery technologies, telemedicine and remote patient monitoring, patient-centric care, combination therapies, collaborative research initiatives.

The increasing prevalence of fungal infections is expected to drive the growth of the candidiasis therapeutics market. Fungal infections, which affect the skin, mucous membranes, and internal organs, are more common in individuals with weakened immune systems. This growing incidence of infections, particularly candidiasis, creates opportunities for manufacturers to develop and provide specialized, effective antifungal drugs that target the underlying pathogens. These drugs aim to alleviate symptoms, prevent complications, promote recovery, reduce the spread of Candida infections in healthcare settings, and improve patient outcomes. For instance, in January 2024, the University of Minnesota, a U.S.-based research institution, reported that fungal infections cause more than 3.75 million deaths annually, with about 2.55 million deaths directly linked to fungal diseases. As a result, the rising number of fungal infections is expected to propel the candidiasis therapeutics market.

The increasing number of clinical trials is expected to further fuel the growth trajectory of the candidiasis therapeutics market. Clinical trials serve as pivotal research studies aimed at assessing the safety and efficacy of novel medical treatments, interventions, drugs, or devices in human subjects. Within the domain of candidiasis therapeutics, these trials play a crucial role by offering a systematic and stringent evaluation platform for testing the safety and effectiveness of potential treatments. As reported by ClinicalTrials.gov in May 2023, the number of registered clinical trials surged to around 437,533 in 2023, compared to 399,499 registered studies in 2022 across all 50 states of the United States and spanning 221 countries. This increase underscores the rising momentum and significance of clinical trials in shaping the landscape of candidiasis therapeutics. Consequently, the burgeoning number of clinical trials emerges as a key factor driving the growth of the candidiasis therapeutics market.

Leading companies operating within the candidiasis therapeutics market are dedicatedly engaged in developing innovative drugs, such as BREXAFEMME (ibrexafungerp tablets), aimed at mitigating the occurrence of recurrent vulvovaginal candidiasis (RVVC) in adult women. BREXAFEMME (ibrexafungerp tablets) constitutes an oral, non-azole medication designed for the treatment of vulvovaginal candidiasis (VVC) and reducing the incidence of recurrent vulvovaginal candidiasis (RVVC), commonly known as chronic yeast infections. For instance, in December 2022, Scynexis Inc., a prominent US-based pharmaceutical company, secured approval from the US Food and Drug Administration (FDA) for BREXAFEMME (ibrexafungerp tablets). The medication targets Candida albicans, the fungus responsible for VVC, by obstructing its growth. Notably, BREXAFEMME is deemed a safe and effective treatment option for vulvovaginal candidiasis (VVC), available solely through prescription, with a recommended dosage of one 150-mg capsule taken orally once daily for a single day. This innovative drug stands as a promising advancement in addressing candidiasis, offering a viable treatment solution while navigating potential concerns related to adverse drug effects.

In May 2023, GSK plc, a prominent UK-based pharmaceutical company, finalized the acquisition of Licensing rights for ibrexafungerp from Scynexism Inc. in a transaction amounting to $90 million. This strategic acquisition grants GSK exclusive rights to further the development and commercialization of ibrexafungerp drugs, a groundbreaking antifungal medication designed for the treatment of vulvovaginal candidiasis (VVC). The acquisition is aimed at expediting the advancement and market availability of ibrexafungerp. Scynexism Inc., a notable US-based pharmaceutical company specializing in therapeutic solutions for fungal diseases, including candidiasis, initially developed this innovative medication.

Major companies operating in the candidiasis therapeutics market report are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.

North America was the largest region in the candidiasis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the candidiasis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The candidiasis therapeutics market consists of revenues earned by entities by providing services such as medication services, diagnostic tests, consultation services, and medical monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The candidiasis therapeutics market also includes sales of topical creams and ointments, oral medications, medical devices, probiotics, nutritional supplements and antifungal medications that are used in providing these services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Candidiasis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on candidiasis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for candidiasis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The candidiasis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Medication; Surgery; Other Treatments
• 2) By Anatomy Type: Oral Candidiasis; Vulvovaginal Candidiasis; Cutaneous Candidiasis; Invasive Candidiasis; Systemic Candidiasis
• 3) By Mode Of Administration: Injectable; Oral; Other Mode Of Administrations
• 4) By Patient Population: Adults; Pediatrics
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Medication: Antifungal Drugs; Topical Treatments; Systemic Treatments
• 2) By Surgery: Surgical Debridement; Organ Removal
• 3) By Other Treatments: Probiotics; Home Remedies; Lifestyle Modifications
• Companies Mentioned: Pfizer Inc.; Biocon Limited; Torrent Pharmaceuticals Ltd.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Candidiasis Therapeutics Market Characteristics

3. Candidiasis Therapeutics Market Trends And Strategies

4. Candidiasis Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Candidiasis Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Candidiasis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Candidiasis Therapeutics Market Growth Rate Analysis
• 5.4. Global Candidiasis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Candidiasis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Candidiasis Therapeutics Total Addressable Market (TAM)

6. Candidiasis Therapeutics Market Segmentation

• 6.1. Global Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Surgery
• Other Treatments
• 6.2. Global Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Candidiasis
• Vulvovaginal Candidiasis
• Cutaneous Candidiasis
• Invasive Candidiasis
• Systemic Candidiasis
• 6.3. Global Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable
• Oral
• Other Mode Of Administrations
• 6.4. Global Candidiasis Therapeutics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adults
• Pediatrics
• 6.5. Global Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Candidiasis Therapeutics Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antifungal Drugs
• Topical Treatments
• Systemic Treatments
• 6.7. Global Candidiasis Therapeutics Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Debridement
• Organ Removal
• 6.8. Global Candidiasis Therapeutics Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Probiotics
• Home Remedies
• Lifestyle Modifications

7. Candidiasis Therapeutics Market Regional And Country Analysis

• 7.1. Global Candidiasis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Candidiasis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Candidiasis Therapeutics Market

• 8.1. Asia-Pacific Candidiasis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Candidiasis Therapeutics Market

• 9.1. China Candidiasis Therapeutics Market Overview
• 9.2. China Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Candidiasis Therapeutics Market

• 10.1. India Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Candidiasis Therapeutics Market

• 11.1. Japan Candidiasis Therapeutics Market Overview
• 11.2. Japan Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Candidiasis Therapeutics Market

• 12.1. Australia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Candidiasis Therapeutics Market

• 13.1. Indonesia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Candidiasis Therapeutics Market

• 14.1. South Korea Candidiasis Therapeutics Market Overview
• 14.2. South Korea Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Candidiasis Therapeutics Market

• 15.1. Western Europe Candidiasis Therapeutics Market Overview
• 15.2. Western Europe Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Candidiasis Therapeutics Market

• 16.1. UK Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Candidiasis Therapeutics Market

• 17.1. Germany Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Candidiasis Therapeutics Market

• 18.1. France Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Candidiasis Therapeutics Market

• 19.1. Italy Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Candidiasis Therapeutics Market

• 20.1. Spain Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Candidiasis Therapeutics Market

• 21.1. Eastern Europe Candidiasis Therapeutics Market Overview
• 21.2. Eastern Europe Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Candidiasis Therapeutics Market

• 22.1. Russia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Candidiasis Therapeutics Market

• 23.1. North America Candidiasis Therapeutics Market Overview
• 23.2. North America Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Candidiasis Therapeutics Market

• 24.1. USA Candidiasis Therapeutics Market Overview
• 24.2. USA Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Candidiasis Therapeutics Market

• 25.1. Canada Candidiasis Therapeutics Market Overview
• 25.2. Canada Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Candidiasis Therapeutics Market

• 26.1. South America Candidiasis Therapeutics Market Overview
• 26.2. South America Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Candidiasis Therapeutics Market

• 27.1. Brazil Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Candidiasis Therapeutics Market

• 28.1. Middle East Candidiasis Therapeutics Market Overview
• 28.2. Middle East Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Candidiasis Therapeutics Market

• 29.1. Africa Candidiasis Therapeutics Market Overview
• 29.2. Africa Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Candidiasis Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Candidiasis Therapeutics Market Competitive Landscape
• 30.2. Candidiasis Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Biocon Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Torrent Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Candidiasis Therapeutics Market Other Major And Innovative Companies

• 31.1. AbbVie Inc.
• 31.2. Bayer AG
• 31.3. Novartis AG
• 31.4. Sanofi S.A.
• 31.5. AstraZeneca plc.
• 31.6. GSK plc.
• 31.7. Amgen Inc.
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Astellas Pharma Inc.
• 31.10. Cipla Inc.
• 31.11. Bruker Corporation
• 31.12. Lupin Limited
• 31.13. Galapagos NV
• 31.14. Basilea Pharmaceutica Ltd.
• 31.15. WOCKHARDT Limited

32. Global Candidiasis Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Candidiasis Therapeutics Market

34. Recent Developments In The Candidiasis Therapeutics Market

35. Candidiasis Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Candidiasis Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Candidiasis Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Candidiasis Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer